血钙的检测在尼莫地平治疗脑梗塞中的价值探讨

Value of Measurement of Plasma Calcium in the treatment of Cerebral Infarction with Nimodipine

尼莫地平（Ｎｉｍｏｄｉｐｉｎｅ）在动物实验方面已显示出较好的神经保护作用。近年来已开始应用于临床。为了寻求在临床上有效的和实用的监测指标，我们对３５例应用Ｎｉｍｏｄｉｐｉｎｅ治疗的脑梗塞病人进行了治疗前后血浆Ｃａ２＋的检测，同时与２８例非Ｎｉｍｏｄｉｐｉｎｅ治疗的病人进行对照。结果显示：Ｎｉｍｏｄｉｐｉｎｅ治疗组病人治疗前血浆Ｃａ２＋为２．０７６６±０．３３６４ｍｍｏｌ／ｌ，治疗后血Ｃａ２＋为２．２５３３±０．５６９５ｍｍｏｌ／Ｌ．经过统计学处理，治疗前后血Ｃａ２＋有显著性差异（Ｐ＜０．００１）。与非Ｎｉ－ｍｏｄｉｐｉｎｅ治疗组比较，虽然后者治疗后血Ｃａ２＋也发生了变化，但不如Ｎｉｍｏｄｉｐｉｎｅ组变化明显（Ｐ＜０．０５）。

It was showed that Nimodopine had good effectof neuroal protection in animal experiments and was well applied clinically. In order to search for effective and practical indication, the concentration of plasma calcium was measured in 35 cases of cerebral infarctionwho were treated with Nimodipine pre- and post-therapeutically. Twenty-eight cases of cerebral infarction with non-nimdipine were as controls. The result showed that the concentation of the plasma Ca 2+ in the nimodipine group was 2.0766±0.3364 mmol/L and 2.2533±0.5695 mmol/l before and after therapy, rspectively, in which there was significant difference statistically ( P <0.01). The alteration of plasma Ca in non-nimodipine group also occured, but less significant than that in the nimodipine group ( P <0.05). we concluded that the measurement of plasma Ca may be served as an index in evaluating the treatment of nimodipine for the patients with cerebral infarction.